Skip to main content

Headache and Neurological Pain

Our research group is focused on studying the pathophysiology of migraine and other primary headaches using preclinical, translational and clinical research.

Migraine will allow us to define the brain’s adaptive, sensory/cognitive functions, through genetics, epigenetics, neurophysiology, neuromolecular and neuroanatomical information with an interest in developing clinical therapeutic solutions, with the goal on having an impact on suffering and increasing the well-being.

Team

Laila Asskour

Laila Asskour

Research technician
Headache and Neurological Pain
Read more
Nara Ikumi Montserrat

Nara Ikumi Montserrat

Postdoctoral researcher
Headache and Neurological Pain
Read more
Raquel Maria Lastra Borras

Raquel Maria Lastra Borras

Research technician
Headache and Neurological Pain
Read more
Victor José Gallardo Lopez

Victor José Gallardo Lopez

Research technician
Headache and Neurological Pain
Read more
Laila Asskour

Laila Asskour

Research technician
Headache and Neurological Pain
Read more
Nara Ikumi Montserrat

Nara Ikumi Montserrat

Postdoctoral researcher
Headache and Neurological Pain
Read more
Raquel Maria Lastra Borras

Raquel Maria Lastra Borras

Research technician
Headache and Neurological Pain
Read more
Victor José Gallardo Lopez

Victor José Gallardo Lopez

Research technician
Headache and Neurological Pain
Read more

Projects

Fenotipado molecular de pacientes con migrañA según edad y Sexo a través de la cuanTificación de CGRP en saliva para realizar medicina de precisión: estudio FAST.

IP: Patricia Pozo Rosich
Collaborators: Alicia Alpuente Ruiz, Laila Asskour, Eulalia Gine Cipres, Victor José Gallardo Lopez, Edoardo Caronna, Laura Gómez Dabó
Funding agency: Instituto de Salud Carlos III
Funding: 81070
Reference: PI22/01501
Duration: 01/01/2023 - 31/12/2025

Publications

Dynamic fluctuations of salivary CGRP levels during migraine attacks: association with clinical variables and phenotypic characterization.

PMID: 38637736
Journal: JOURNAL OF HEADACHE AND PAIN
Year: 2024
Reference: J Headache Pain. 2024 Apr 18;25(1):58. doi: 10.1186/s10194-024-01772-9.
Impact factor:
Publication type: Paper in international publication
Authors: Alpuente, Alicia; Asskour, Laila; Caronna, Edoardo; Gallardo, Victor J; Pozo-Rosich, Patricia; Torres-Ferrus, Marta et al.
DOI: 10.1186/s10194-024-01772-9

Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world.

PMID: 38777579
Journal: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
Year: 2024
Reference: J Neurol Neurosurg Psychiatry. 2024 May 22:jnnp-2023-333295. doi: 10.1136/jnnp-2023-333295.
Impact factor:
Publication type: Paper in international publication
Authors: Alpuente, Alicia; Alvarez Escudero, Maria Rocio; Aurilia, Cinzia; Barbanti, Piero; Beltran Blasco, Isabel; Broadhurst, Sarah; Cabral, Goncalo; Campoy, Sergio; Caronna, Edoardo; Castellanos, Candela Nieves et al.
DOI: 10.1136/jnnp-2023-333295

Effectiveness and Safety of OnabotulinumtoxinA in Adolescent Patients with Chronic Migraine.

PMID: 38787073
Journal: Toxins
Year: 2024
Reference: Toxins (Basel). 2024 May 11;16(5):221. doi: 10.3390/toxins16050221.
Impact factor:
Publication type: Paper in international publication
Authors: Alpuente, Alicia; Caronna, Edoardo; Gallardo, Victor J; Gomez-Dabo, Laura; Mas-de-Les-Valls, Rut; Pozo-Rosich, Patricia; Torres-Ferrus, Marta et al.
DOI: 10.3390/toxins16050221

Behavioral therapy in migraine: Expanding the therapeutic arsenal.

PMID: 39034641
Journal: EUROPEAN JOURNAL OF NEUROLOGY
Year: 2024
Reference: Eur J Neurol. 2024 Jul 21:e16414. doi: 10.1111/ene.16414.
Impact factor:
Publication type: Paper in international publication
Authors: Barandiaran, Myriam; Bengoetxea, Ana; de Munain, Estibaliz Lopez; Dias, Patricia Alves; Garcia-Martin, Valvanuz; Grozeva, Vesselina; Laspra-Solis, Carmen; Minguez-Olaondo, Ane; Vila-Pueyo, Marta; Villalba, Ines Martin et al.
DOI: 10.1111/ene.16414

Causal relationships between migraine and microstructural white matter: a Mendelian randomization study.

PMID: 36793015
Journal: JOURNAL OF HEADACHE AND PAIN
Year: 2023
Reference: J Headache Pain. 2023 Feb 16;24(1):10. doi: 10.1186/s10194-023-01550-z.
Impact factor:
Publication type: Paper in international publication
Authors: Anttila, Verneri; Artto, Ville; Belin, Andrea C; Bjornsdottir, Anna; Bjornsdottir, Gyda; Boomsma, Dorret I; Borte, Sigrid; Cao, Jin; Chalmer, Mona A; Chasman, Daniel I et al.
DOI: 10.1186/s10194-023-01550-z

A study of differential microRNA expression profile in migraine: the microMIG exploratory study.

PMID: 36797674
Journal: JOURNAL OF HEADACHE AND PAIN
Year: 2023
Reference: J Headache Pain. 2023 Feb 17;24(1):11. doi: 10.1186/s10194-023-01542-z.
Impact factor:
Publication type: Paper in international publication
Authors: Alpuente, A; Asskour, L; Caronna, E; Gallardo, V J; Gomez-Galvan, J B; Gomez-Galvan, J B; Pozo-Rosich, P; Torres-Ferrus, M et al.
DOI: 10.1186/s10194-023-01542-z

Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials.

PMID: 36855951
Journal: CEPHALALGIA
Year: 2023
Reference: Cephalalgia. 2023 Apr;43(4):3331024231159366. doi: 10.1177/03331024231159366.
Impact factor:
Publication type: Review in international publication
Authors: Garcia-Azorin, David; Haghdoost, Faraidoon; Huessler, Eva-Maria; Messina, Roberta; Pozo-Rosich, Patricia; Puledda, Francesca et al.
DOI: 10.1177/03331024231159366

Patterns of response to anti-CGRP monoclonal antibodies during first 6-months of treatment in resistant migraine patients: impact on outcome.

PMID: 37038303
Journal: EUROPEAN JOURNAL OF NEUROLOGY
Year: 2023
Reference: Eur J Neurol. 2023 Jul;30(7):1937-1944. doi: 10.1111/ene.15816. Epub 2023 Apr 26.
Impact factor:
Publication type: Paper in international publication
Authors: Alpuente, Alicia; Caronna, Edoardo; Gallardo, Victor J; Gine-Cipres, Eulalia; Pozo-Rosich, Patricia; Torres-Ferrus, Marta et al.
DOI: 10.1111/ene.15816

Salivary CGRP and Erenumab Treatment Response: Towards Precision Medicine in Migraine.

PMID: 36054144
Journal: ANNALS OF NEUROLOGY
Year: 2022
Reference: Ann Neurol. 2022 Nov;92(5):846-859. doi: 10.1002/ana.26472. Epub 2022 Aug 24.
Impact factor:
Publication type: Paper in international publication
Authors: Alpuente, Alicia; Asskour, Laila; Caronna, Edoardo; Gallardo, Victor J; Pozo-Rosich, Patricia; Torres-Ferrus, Marta et al.
DOI: 10.1002/ana.26472

The relationship of headache as a symptom to COVID-19 survival: A systematic review and meta-analysis of survival of 43,169 inpatients with COVID-19.

PMID: 36053077
Journal: HEADACHE
Year: 2022
Reference: Headache. 2022 Sep;62(8):1019-1028. doi: 10.1111/head.14376. Epub 2022 Sep 2.
Impact factor:
Publication type: Paper in international publication
Authors: Caronna, Edoardo; Gallardo, Victor J; Pozo-Rosich, Patricia; Shapiro, Robert E et al.
DOI: 10.1111/head.14376

Interest in and exposure to headache disorders among neurology residents in Denmark: A nationwide cross-sectional survey.

PMID: 36004408
Journal: ACTA NEUROLOGICA SCANDINAVICA
Year: 2022
Reference: Acta Neurol Scand. 2022 Nov;146(5):568-572. doi: 10.1111/ane.13681. Epub 2022 Aug 11.
Impact factor:
Publication type: Paper in international publication
Authors: Amin, Faisal Mohammad; Do, Thien Phu; Kristensen, Malene Glavind Holmsted; Pozo-Rosich, Patricia et al.
DOI: 10.1111/ane.13681

Association of a Cyclical Migraine Phenotype With Disease Progression: A One-Year Time Series Analysis.

PMID: 35953289
Journal: NEUROLOGY
Year: 2022
Reference: Neurology. 2022 Sep 20;99(12):e1326-e1334. doi: 10.1212/WNL.0000000000200887. Epub 2022 Aug 11.
Impact factor:
Publication type: Paper in international publication
Authors: Alpuente, Alicia; Gallardo, Victor J; Pozo-Rosich, Patricia et al.
DOI: 10.1212/WNL.0000000000200887

Is There a Gender Difference in the Response to onabotulinumtoxinA in Chronic Migraine? Insights from a Real-Life European Multicenter Study on 2879 Patients.

PMID: 34564833
Journal: Pain and Therapy
Year: 2021
Reference: Pain Ther. 2021 Dec;10(2):1605-1618. doi: 10.1007/s40122-021-00328-y. Epub 2021 Sep 26.
Impact factor:
Publication type: Paper in international publication
Authors: Ahmed, Fayyaz; Alpuente, Alicia; Andreou, Anna P; Baraldi, Carlo; Brunelli, Nicoletta; Butera, Calogera; Cevoli, Sabina; Colombo, Bruno; Filatova, Elena; Filippi, Massimo et al.
DOI: 10.1007/s40122-021-00328-y

Toward a better understanding of persistent headache after mild COVID-19: Three migraine-like yet distinct scenarios.

PMID: 34363619
Journal: HEADACHE
Year: 2021
Reference: Headache. 2021 Sep;61(8):1277-1280. doi: 10.1111/head.14197. Epub 2021 Aug 7.
Impact factor:
Publication type: Letter or abstract
Authors: Alpuente, Alicia; Caronna, Edoardo; Pozo-Rosich, Patricia; Torres-Ferrus, Marta et al.
DOI: 10.1111/head.14197

Cortical metabolic and structural differences in patients with chronic migraine. An exploratory (18)FDG-PET and MRI study.

PMID: 34273945
Journal: JOURNAL OF HEADACHE AND PAIN
Year: 2021
Reference: J Headache Pain. 2021 Jul 17;22(1):75. doi: 10.1186/s10194-021-01289-5.
Impact factor:
Publication type: Paper in international publication
Authors: Alpuente, Alicia; Caronna, Edoardo; Castell-Conesa, Joan; Cuberas-Borros, Gemma; Gallardo, Victor J; Lorenzo-Bosquet, Carles; Pareto, Deborah; Pozo-Rosich, Patricia; Rovira, Alex; Torres-Ferrus, Marta et al.
DOI: 10.1186/s10194-021-01289-5

MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention.

PMID: 34273947
Journal: JOURNAL OF HEADACHE AND PAIN
Year: 2021
Reference: J Headache Pain. 2021 Jul 17;22(1):74. doi: 10.1186/s10194-021-01267-x.
Impact factor:
Publication type: Paper in international publication
Authors: Alberte-Woodward, Miguel; Alpuente, Alicia; Beltran, Isabel; Belvis, Robert; Cano, Antonio; Cuadrado, Elisa; de Teran, Javier Diaz; Del Rio, Margarita Sanchez; Ezpeleta, David; Gomez-Camello, Angel et al.
DOI: 10.1186/s10194-021-01267-x

Impact of Puberty in Pediatric Migraine: A Pilot Prospective Study.

PMID: 32657062
Journal: Journal of Clinical Neurology
Year: 2020
Reference: J Clin Neurol. 2020 Jul;16(3):416-422. doi: 10.3988/jcn.2020.16.3.416.
Impact factor:
Publication type: Paper in international publication
Authors: Fonseca, Elena; Gallardo, Victor Jose; Macaya, Alfons; Pozo-Rosich, Patricia; Torres-Ferrus, Marta et al.
DOI: 10.3988/jcn.2020.16.3.416

Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA.

PMID: 32652924
Journal: JOURNAL OF HEADACHE AND PAIN
Year: 2020
Reference: J Headache Pain. 2020 Jul 11;21(1):88. doi: 10.1186/s10194-020-01157-8.
Impact factor:
Publication type: Paper in international publication
Authors: Alpuente, Alicia; Gallardo, Victor Jose; Pozo-Rosich, Patricia; Torres-Ferrus, Marta et al.
DOI: 10.1186/s10194-020-01157-8

Estimating the Savings of a Migraine Free Life: Results from the Spanish Atlas.

PMID: 32643853
Journal: EUROPEAN JOURNAL OF NEUROLOGY
Year: 2020
Reference: Eur J Neurol. 2020 Dec;27(12):2616-2624. doi: 10.1111/ene.14431. Epub 2020 Aug 8.
Impact factor:
Publication type: Paper in international publication
Authors: Blanch, C; Brace, O; Colomina, I; Garrido-Cumbrera, M; Irimia, P; Pozo-Rosich, P; Santos-Lasaosa, S et al.
DOI: 10.1111/ene.14431

How and when to refer patients diagnosed with secondary headache and other craniofacial pain in the Emergency Department and Primary Care: Recommendations of the Spanish Society of Neurology's Headache Study Group.

PMID: 28870392
Journal: NEUROLOGIA
Year: 2020
Reference: Neurologia. 2020 Jun;35(5):323-331. doi: 10.1016/j.nrl.2017.08.002. Epub 2017 Sep 1.
Impact factor:
Publication type: Review in national publication
Authors: Diaz de Teran, J; Gago-Veiga, A B; Gonzalez-Garcia, N; Gonzalez-Oria, C; Gonzalez-Quintanilla, V; Minguez-Olaondo, A; Pozo-Rosich, P; Santos-Lasaosa, S; Viguera Romero, J et al.
DOI: 10.1016/j.nrl.2017.08.002

Quality assurance in specialized headache units in Spain: an observational prospective study.

PMID: 31238877
Journal: JOURNAL OF HEADACHE AND PAIN
Year: 2019
Reference: J Headache Pain. 2019 Jun 25;20(1):73. doi: 10.1186/s10194-019-1020-1.
Impact factor:
Publication type: Paper in international publication
Authors: Balseiro-Gomez, Jose; Guerrero-Peral, Angel L; Ignacio, Emilio; Latorre-Gonzalez, German; Layos-Romero, Almudena; Lucas, Cesar; Martinez-Garcia, Alba; Mira, Jose J; Pascual, Julio; Porta-Etessam, Jesus et al.
DOI: 10.1186/s10194-019-1020-1

Early efficacy and late gain in chronic and high-frequency episodic migraine with OnabotulinumtoxinA.

PMID: 31220392
Journal: EUROPEAN JOURNAL OF NEUROLOGY
Year: 2019
Reference: Eur J Neurol. 2019 Dec;26(12):1464-1470. doi: 10.1111/ene.14028. Epub 2019 Jul 18.
Impact factor:
Publication type: Paper in international publication
Authors: Alpuente, Alicia; Alvarez-Sabin, Jose; Gallardo, Victor Jose; Pozo-Rosich, Patricia; Torres-Ferrus, Marta et al.
DOI: 10.1111/ene.14028

Self-reported periodontitis and migraine: results from a multicenter, cross-sectional survey in Spain.

PMID: 31030294
Journal: Odontology
Year: 2019
Reference: Odontology. 2019 Oct;107(4):530-535. doi: 10.1007/s10266-019-00430-w. Epub 2019 Apr 27.
Impact factor:
Publication type: Paper in international publication
Authors: Alvaro, Luis Carlos; Belvis, Roberto; Blanco, Juan; Cuadrado, Maria Luz; D'Aiuto, Francesco; Gago-Veiga, Ana Beatriz; Garcia-Azorin, David; Gonzalez-Oria, Carmen; Guerrero, Angel; Lainez, Jose Miguel et al.
DOI: 10.1007/s10266-019-00430-w

How much do calcitonin gene-related peptide monoclonal antibodies improve the quality of life in migraine? A patient's perspective.

PMID: 30950844
Journal: CURRENT OPINION IN NEUROLOGY
Year: 2019
Reference: Curr Opin Neurol. 2019 Jun;32(3):395-404. doi: 10.1097/WCO.0000000000000689.
Impact factor:
Publication type: Paper in international publication
Authors: Alpuente, Alicia; Pozo-Rosich, Patricia; Torres-Ferrus, Marta et al.
DOI: 10.1097/WCO.0000000000000689

Cost of status epilepticus (SE): Effects of delayed treatment and SE duration.

PMID: 30384104
Journal: EPILEPSY & BEHAVIOR
Year: 2018
Reference: Epilepsy Behav. 2018 Dec;89:8-14. doi: 10.1016/j.yebeh.2018.09.046. Epub 2018 Oct 26.
Impact factor:
Publication type: Paper in international publication
Authors: Abarrategui, Belen; Abraira, Laura; Alpuente, Alicia; Garcia-Morales, Irene; Gutierrez-Viedma, Alvaro; Mazuela, Gonzalo; Parejo, Beatriz; Quintana, Manuel; Salas-Puig, Xavier; Santamarina, Estevo et al.
DOI: 10.1016/j.yebeh.2018.09.046

Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation.

PMID: 30259200
Journal: JOURNAL OF HEADACHE AND PAIN
Year: 2018
Reference: J Headache Pain. 2018 Sep 26;19(1):91. doi: 10.1186/s10194-018-0921-8.
Impact factor:
Publication type: Paper in international publication
Authors: Ahmed, Fayyaz; Ashina, Messoud; Bendtsen, Lars; Martelletti, Paolo; Mitsikostas, Dimos; Pozo-Rosich, Patricia; Sacco, Simona et al.
DOI: 10.1186/s10194-018-0921-8

Myasthenia gravis following alemtuzumab therapy for multiple sclerosis.

PMID: 30143565
Journal: NEUROLOGY
Year: 2018
Reference: Neurology. 2018 Sep 25;91(13):622-624. doi: 10.1212/WNL.0000000000006251. Epub 2018 Aug 24.
Impact factor:
Publication type: Paper in international publication
Authors: Caronna, Edoardo; Gratacos, Margarida; Midaglia, Luciana; Montalban, Xavier; Raguer, Nuria; Sastre-Garriga, Jaume; Tintore, Mar et al.
DOI: 10.1212/WNL.0000000000006251

Unilateral pain and shorter duration of chronic migraine are significant predictors of response to onabotulinumtoxin A.

PMID: 29575364
Journal: EUROPEAN JOURNAL OF NEUROLOGY
Year: 2018
Reference: Eur J Neurol. 2018 Apr;25(4):e48. doi: 10.1111/ene.13570.
Impact factor:
Publication type: Letter or abstract
Authors: Dominguez, C; Leira, R; Leira, Y; Pozo-Rosich, P et al.
DOI: 10.1111/ene.13570

Blog

News

Two international studies led by Vall d'Hebron recommend early administration of specific drugs to prevent migraine to achieve a better response to therapy.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

The study, conducted in more than 770 people, concludes that atogepant reduces the frequency of migraine attacks and the need to take medication.